News headlines about Sucampo Pharmaceuticals (NASDAQ:SCMP) have trended somewhat negative recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a daily sentiment score of -0.01 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.2056755276527 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of equities research analysts recently commented on the company. Nomura reaffirmed a “neutral” rating and set a $18.00 target price on shares of Sucampo Pharmaceuticals in a report on Friday, January 26th. Maxim Group downgraded Sucampo Pharmaceuticals to a “hold” rating in a report on Monday, January 1st. ValuEngine raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. BidaskClub downgraded Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 14th. Finally, Zacks Investment Research downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 9th. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Sucampo Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $20.73.
Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at $18.00 on Friday. Sucampo Pharmaceuticals has a twelve month low of $9.30 and a twelve month high of $18.75. The stock has a market capitalization of $839.46, a P/E ratio of -5.37, a price-to-earnings-growth ratio of 5.06 and a beta of 1.38. The company has a debt-to-equity ratio of 7.37, a current ratio of 5.11 and a quick ratio of 4.46.
COPYRIGHT VIOLATION NOTICE: “Somewhat Negative News Coverage Somewhat Unlikely to Impact Sucampo Pharmaceuticals (SCMP) Share Price” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://ledgergazette.com/2018/03/18/somewhat-negative-news-coverage-somewhat-unlikely-to-impact-sucampo-pharmaceuticals-scmp-share-price.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.